| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Aurora Daljit Singh | Title: Chief Operating and Development Officer | C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN | /s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora | 2025-11-13 | 0001793971 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NMRA | Common Stock | Sale | -$307K | -115K | -100% | $2.68 | 0 | Nov 11, 2025 | See footnote | F1, F2, F3 |
| holding | NMRA | Common Stock | 88.9K | Nov 11, 2025 | Direct |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024. |
| F2 | This transaction was executed in multiple trades in prices ranging from $2.65 to $2.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F3 | Shares held by Aurora Family Trust. |
Title: Chief Operating and Development Officer